PD-1

[Xilio Therapeutics, Inc.] Xilio Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment.

[Journal of Pathology Clinical Research] The authors investigated the expression of two PD-1 ligands, PD-L1 and PD-L2, in pancreatic ductal adenocarcinoma, analysed their role in survival, and explored their correlation with clinicopathological features, immune infiltration, and DNA damage response molecules.

[Evaxion Biotech A/S] Evaxion Biotech A/S announced it received clearance from the Australia Therapeutic Goods Administration to initiate a Phase IIb trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s anti-PD-1 therapy KEYTRUDA®.

[IMV Inc.] IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.

[Molecular Therapy Oncolytics] Non-viral/plasmid-based programmed cell death protein 1 (PD-1) knockout was carried out immediately prior to the traditional 14-day tumor-infiltrating lymphocytes-based ACT rapid expansion protocol.

[Science Immunology] Scientists described a population of CXCR5+ T follicular helper–like mucosal-associated invariant T (MAIT) cells that have the capacity to provide B cell help within mucosal lymphoid organs.